Reply to thread

Pretty clear the head of QA has no clue on what a quality issue is.  To whitewash this and suggest it is a "one off" is absurd.  The next debacle will be with "rozimab" and shortly after that the Boston acquisition zilucoplan.  Ownership begins at the top.  Start with head of QA and work backwards.